Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA commissioner with experience akin to drug advisory cmte. chair suggested by NDMA.

This article was originally published in The Tan Sheet

Executive Summary

FDA COMMISSIONER SEARCH: DRUG ADVISORY CMTE. CHAIR EXPERIENCE cited by the Nonprescription Drug Manufacturers Association as a desirable qualification for the future FDA head. In a Feb. 4 letter to HHS Secretary Donna Shalala, NDMA recommends that the new commissioner have "a recognized expertise in managing sensitive medical and scientific issues, as might be found in a person who had served as chairman to a drug advisory committee." Among the names that have been circulated as a possible successor to retiring FDA Commissioner David Kessler, MD, is former Nonprescription Drugs Advisory Committee Chair Randy Juhl, PhD, dean of the University of Pittsburgh School of Pharmacy ("The Tan Sheet" Dec. 9, 1996, p. 11).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS086718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel